Dronabinol

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1985

www.ebi.ac.uk

First approval year: 1985
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Dronabinol
www.ebi.ac.uk

Molecular weight: 314.47
www.ebi.ac.uk

Structure (SMILES): CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21
www.ebi.ac.uk

dronabinol
Dronabinol
dronabinol component of ad 313
Dronabinol component of ad-313
dronabinol component of ad313
Dronabinol component of ad313
dronabinol component of sci 110
Dronabinol component of sci-110
marinol
Marinol
syndros
Syndros

.delta.-9-tetrahydrocannabinol
.delta.1-thc
.delta.9-tetrahydrocannabinol
.delta.9-thc
(-)-3,4-trans-Δ1-Tetrahydrocannabinol
(-)-trans-Tetrahydrocannabinol
(-)-trans-Δ1-Tetrahydrocannabinol
(-)-trans-Δ9-Tetrahydrocannabinol
(-)-trans-Δ9-THC
(-)-Δ1-Tetrahydrocannabinol
(-)-Δ9-Tetrahydrocannabinol
(-)-Δ9-THC
(-)-Δ9-trans-Tetrahydrocannabinol
(6AR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
(6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
(l)-Δ1-Tetrahydrocannabinol
∆9-tetrahydrocannabinol
10 mg Δ9-tetrahydrocannabinol (THC)
2 mg Delta-9-THC
3 4 trans δ1 tetrahydrocannabinol
4 mg Delta-9-THC
6ar 10ar 6 6 9 trimethyl 3 pentyl 6a 7 8 10a tetrahydro 6h benzo c chromen 1 ol
6ar 10ar 6a 7 8 10a tetrahydro 6 6 9 trimethyl 3 pentyl 6h dibenzo b d pyran 1 ol
9 tetrahydrocannabinol
abbott 40566

And 121 more, listed on the interactive page.

ATC classification codes

A04AD10

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

1972-08-3

ChEMBL ID: CHEMBL465
www.ebi.ac.uk

InChIKey: CYQFCXCEBYINGO-IAGOWNOFSA-N
www.ebi.ac.uk

PubChem compound IDs

16078

RxNorm IDs (RxCUI)

10402

FDA ingredient codes (UNII)

7J8897W37S

Applicant: ALKEM LABS LTD
Approval date: 31 May 1985
Application number: NDA018651

Patents: 4
Designations: 3
Earliest recorded loss of exclusivity: 6 Aug 2028
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only

Pharmacology name: Δ9-tetrahydrocannabinol
Type: Natural product
Drug name stem: -nab-
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Action type
Agonist
Target
TRPA1
Gene symbol
TRPA1
Action
Agonist
Action type
Agonist
Target
TRPA1
Gene symbol
TRPA1
Protein identifier
O75762
Median affinity
4.9
Affinity units
pEC50
Action
Agonist
Action type
Agonist
Target
GPR55
Gene symbol
GPR55
Protein identifier
Q9Y2T6
Median affinity
8.1
Affinity units
pEC50
Mechanism
Cannabinoid CB1 receptor agonist
Action type
Agonist
Target
Cannabinoid receptor 1
Protein identifier
P21554
Action
Channel blocker
Action type
Channel blocker
Target
TRPM8
Gene symbol
TRPM8
Protein identifier
Q7Z2W7
Action type
FULL_AGONIST
Target
GPR18
Gene symbol
GPR18
Action
Full agonist
Action type
FULL_AGONIST
Target
GPR18
Gene symbol
GPR18
Protein identifier
Q14330
Median affinity
6.02
Affinity units
pEC50
Action type
NONE
Target
TRPM8
Gene symbol
TRPM8
Action type
PARTIAL_AGONIST
Target
CB2 receptor
Gene symbol
CB2 receptor
Action
Partial agonist
Action type
PARTIAL_AGONIST
Target
CB1 receptor
Gene symbol
CNR1
Protein identifier
P21554
Affinity units
pKi
Primary target
Yes
Action
Partial agonist
Action type
PARTIAL_AGONIST
Target
CB2 receptor
Gene symbol
CNR2
Protein identifier
P34972
Affinity units
pKi
Action type
POTENTIATION
Target
glycine receptor α1 subunit
Gene symbol
glycine receptor α1 subunit
Action type
POTENTIATION
Target
glycine receptor α2 subunit
Gene symbol
glycine receptor α2 subunit
Action type
POTENTIATION
Target
glycine receptor α3 subunit
Gene symbol
glycine receptor α3 subunit
Action
Potentiation
Action type
POTENTIATION
Target
glycine receptor α3 subunit
Gene symbol
GLRA3
Protein identifier
O75311
Median affinity
5.3
Affinity units
pEC50
Action
Potentiation
Action type
POTENTIATION
Target
glycine receptor α1 subunit
Gene symbol
GLRA1
Protein identifier
P23415
Median affinity
5.5
Affinity units
pEC50
Action
Potentiation
Action type
POTENTIATION
Target
glycine receptor α2 subunit
Gene symbol
GLRA2
Protein identifier
P23416
Median affinity
6
Affinity units
pEC50

Open Targets mechanisms

Mechanism
Cannabinoid CB1 receptor agonist
Action type
Agonist
Target
Cannabinoid receptor 1

Action type
ACTIVATOR
Gene symbol
TRPA1
Protein identifier
O75762
Organism
Homo sapiens
Target development level
Clinical
Action type
Agonist
Gene symbol
CNR1
Protein identifier
P21554
Organism
Homo sapiens
Target development level
Clinical
Action type
ALLOSTERIC MODULATOR
Gene symbol
GLRA3
Protein identifier
O75311
Organism
Homo sapiens
Target development level
Chemical evidence
Action type
ALLOSTERIC MODULATOR
Gene symbol
GLRA2
Protein identifier
P23416
Organism
Homo sapiens
Target development level
Chemical evidence

Condition
Irritable Bowel Syndrome
Highest recorded phase
2
Condition identifier
EFO:0000555
Subject identifier
D043183
Condition
Mental Disorders
Highest recorded phase
0.5
Condition identifier
EFO:0000677
Subject identifier
D001523
Condition
Arthritis, Rheumatoid
Highest recorded phase
2
Condition identifier
EFO:0000685
Subject identifier
D001172
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Stress Disorders, Post-Traumatic
Highest recorded phase
2
Condition identifier
EFO:0001358
Subject identifier
D013313
Condition
Essential Tremor
Highest recorded phase
1
Condition identifier
EFO:0003108
Subject identifier
D020329
Condition
Child Development Disorders, Pervasive
Highest recorded phase
2
Condition identifier
EFO:0003756
Subject identifier
D002659
Condition
Arthritis, Psoriatic
Highest recorded phase
2
Condition identifier
EFO:0003778
Subject identifier
D015535
Condition
Pain
Highest recorded phase
2
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Substance-Related Disorders
Highest recorded phase
1
Condition identifier
EFO:0003890
Subject identifier
D019966
Condition
Sleep Apnea, Obstructive
Highest recorded phase
2
Condition identifier
EFO:0003918
Subject identifier
D020181
Condition
Alcohol Drinking
Highest recorded phase
2
Condition identifier
EFO:0004329
Subject identifier
D000428
Condition
Osteoarthritis, Knee
Highest recorded phase
3
Condition identifier
EFO:0004616
Subject identifier
D020370
Condition
Tourette Syndrome
Highest recorded phase
2
Condition identifier
EFO:0004895
Subject identifier
D005879
Condition
Opioid-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0005611
Subject identifier
D009293
Condition
Neuralgia
Highest recorded phase
2
Condition identifier
EFO:0005762
Subject identifier
D009437
Condition
Nausea
Highest recorded phase
4
Condition identifier
EFO:0006911
Subject identifier
D009325
Condition
Marijuana Abuse
Highest recorded phase
2
Condition identifier
EFO:0007191
Subject identifier
D002189
Condition
Torticollis
Highest recorded phase
2
Condition identifier
HP:0000473
Subject identifier
D014103
Condition
Dementia
Highest recorded phase
2
Condition identifier
HP:0000726
Subject identifier
D003704
Condition
Nausea
Highest recorded phase
4
Condition identifier
HP:0002017
Subject identifier
D009325
Condition
Vomiting
Highest recorded phase
4
Condition identifier
HP:0002017
Subject identifier
D014839
Condition
Nausea
Highest recorded phase
4
Condition identifier
HP:0002018
Subject identifier
D009325
Condition
Anorexia
Highest recorded phase
4
Condition identifier
HP:0002039
Subject identifier
D000855
Condition
Joint Diseases
Highest recorded phase
0.5
Condition identifier
HP:0003040
Subject identifier
D007592

And 14 more, listed on the interactive page.

Condition identifier
EFO_0000555
Highest recorded phase
2
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0001072
Highest recorded phase
1
Condition identifier
EFO_0001358
Highest recorded phase
2
Condition identifier
EFO_0003108
Condition identifier
EFO_0003756
Condition identifier
EFO_0003890
Highest recorded phase
1
Condition identifier
EFO_0003918
Condition identifier
EFO_0004320
Condition identifier
EFO_0004329
Highest recorded phase
2
Condition identifier
EFO_0004616
Highest recorded phase
3
Condition identifier
EFO_0004714
Condition identifier
EFO_0004888
Condition identifier
EFO_0004895
Highest recorded phase
2
Condition identifier
EFO_0005687
Condition identifier
EFO_0005762
Highest recorded phase
3
Condition identifier
EFO_0005940
Condition identifier
EFO_0007191
Condition identifier
EFO_0007585
Highest recorded phase
1
Condition identifier
EFO_0007624
Highest recorded phase
1
Condition identifier
EFO_0008572
Highest recorded phase
1
Condition identifier
EFO_0009574
Highest recorded phase
1
Condition identifier
EFO_0009844
Highest recorded phase
2
Condition identifier
EFO_0010702
Highest recorded phase
3
Condition identifier
EFO_0022861
Highest recorded phase
1

And 96 more, listed on the interactive page.

Event
abnormal behaviour
Reports
30
Reporting signal score
34.1466
Event
aggression
Reports
76
Reporting signal score
134.197
Event
agitation
Reports
116
Reporting signal score
200.731
Event
alcohol abuse
Reports
68
Reporting signal score
295.09
Event
altered state of consciousness
Reports
58
Reporting signal score
119.864
Event
anxiety
Reports
58
Reporting signal score
26.7485
Event
apathy
Reports
18
Reporting signal score
32.2704
Event
apparent death
Reports
16
Reporting signal score
49.2294
Event
behaviour disorder
Reports
11
Reporting signal score
26.3558
Event
bradycardia
Reports
52
Reporting signal score
47.0147
Event
bradypnoea
Reports
19
Reporting signal score
56.1234
Event
c-reactive protein abnormal
Reports
17
Reporting signal score
39.2754
Event
cannabinoid hyperemesis syndrome
Reports
4
Reporting signal score
24.3145
Event
cerebellar ataxia
Reports
4
Reporting signal score
14.7427
Event
coma
Reports
110
Reporting signal score
229.543
Event
confusional state
Reports
66
Reporting signal score
43.7985
Event
congenital visual acuity reduced
Reports
5
Reporting signal score
26.1924
Event
convulsion
Reports
13
Reporting signal score
15.3917
Event
cyanosis
Reports
21
Reporting signal score
31.2429
Event
deafness neurosensory
Reports
13
Reporting signal score
28.9274
Event
decreased appetite
Reports
32
Reporting signal score
43.3562
Event
defaecation disorder
Reports
6
Reporting signal score
27.1664
Event
delusion
Reports
17
Reporting signal score
23.8726
Event
depressed level of consciousness
Reports
57
Reporting signal score
83.7067
Event
diastolic hypotension
Reports
6
Reporting signal score
26.6046

And 56 more, listed on the interactive page.

NCT00079560
clinicaltrials.gov
NCT03550352
clinicaltrials.gov
NCT04920539
clinicaltrials.gov
NCT06034314
clinicaltrials.gov
NCT00123201
clinicaltrials.gov
NCT00153192
clinicaltrials.gov
NCT03215940
clinicaltrials.gov
NCT03766269
clinicaltrials.gov
NCT00217971
clinicaltrials.gov
NCT00373399
clinicaltrials.gov
NCT00373503
clinicaltrials.gov
NCT00403117
clinicaltrials.gov
NCT00438139
clinicaltrials.gov
NCT00480441
clinicaltrials.gov
NCT00490269
clinicaltrials.gov
NCT00708994
clinicaltrials.gov
NCT00743145
clinicaltrials.gov
NCT00893074
clinicaltrials.gov
NCT01020019
clinicaltrials.gov
NCT01037608
clinicaltrials.gov
NCT01041170
clinicaltrials.gov
NCT01394185
clinicaltrials.gov
NCT01598896
clinicaltrials.gov
NCT02709954
clinicaltrials.gov
NCT02710331
clinicaltrials.gov

And 56 more, listed on the interactive page.

Dose: 2.1 mg
Route: Oral
How often: Twice daily

Conditions of use

Take with a full glass of water

Hydrogen bond acceptors: 2
Hydrogen bond donors: 1
Polar surface area: 29.46
Calculated partition coefficient (ALogP): 5.74
Calculated partition coefficient (XLogP): 7
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 1
Rotatable bonds: 4
Heavy atoms: 23
Molecular formula: C21H30O2
Monoisotopic mass: 314.224580195
Natural product: Yes

0904-7144
0904-7145
31722-960
31722-961
31722-962
53097-568
53097-569
53097-570
53097-571
53097-572
53097-573
62135-033
67877-753
67877-754
67877-755
78613-201
85776-201
85776-202

Recorded assays: 672
Active assays: 164

Confirmatory
Other
Summary

Hallucinogens
id.nlm.nih.gov
Psychotropic Drugs
id.nlm.nih.gov
Analgesics, Non-Narcotic
id.nlm.nih.gov
Cannabinoid Receptor Agonists
id.nlm.nih.gov

Distribution coefficient (LogD)

Median: 4.49
Mean: 4.49
Minimum: 4.49
Maximum: 4.49
Unit: unitless
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

LogD

Oral bioavailability

Median: 15
Mean: 15
Minimum: 15
Maximum: 15
Unit: %
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (447)

A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers
A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population
A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
A Study Of Synthetic THC And Sleep
A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

Approved for (1)

Cancer

In development for (30)

Alcohol dependence Phase 1
Alzheimer disease Phase 2
Amyotrophic lateral sclerosis Phase 2
Anorexia nervosa Phase 3
Arthropathy Early phase 1
Autism spectrum disorder Phase 2
Bipolar disorder Phase 1
Cannabis dependence Phase 2
Dementia Phase 2
Drug dependence Phase 1
Essential tremor Phase 1
HIV infectious disease Phase 2
Inherited torticollis Phase 2
Irritable bowel syndrome Phase 2
Mental disorder Early phase 1
Migraine with aura Phase 2
Migraine without aura Phase 2
Multiple sclerosis Phase 2
Neuralgia Phase 2
Obstructive sleep apnea syndrome Phase 2

Targets (1)

CNR1 Cannabinoid CB1 receptor agonist

Dronabinol

Development status

Names and chemistry

Brand names (12)

Other names (146)

Identifiers

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (17)

Open Targets mechanisms

DrugCentral mechanisms (4)

Investigated indications (39)

Open Targets indications (121)

Reported adverse events (81)

Trial references (81)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Biological measurements

Observed measurements

Distribution coefficient (LogD)

Measurement types

Oral bioavailability

Measurement types

Related records

Trials (447)

Approved for (1)

In development for (30)

Other linked conditions (1)

Targets (1)